Rallybio Announces Publication Of Target-Mediated Drug Disposition Modeling And Simulations Informing The RLYB212 Dosing Regimen In Pregnant Women; Dosing Regimen To Be Evaluated In Recently Initiated RLYB212 Phase 2 Clinical Trial
Rallybio Announces Publication Of Target-Mediated Drug Disposition Modeling And Simulations Informing The RLYB212 Dosing Regimen In Pregnant Women; Dosing Regimen To Be Evaluated In Recently Initiated RLYB212 Phase 2 Clinical Trial
— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —
— 在最近啓動的RLYB212 II期臨床試驗中評估的給藥方案 —
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, "Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody," in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology.
Rallybio公司（納斯達克: RLYB）是一家臨床階段的生物技術公司，將科學進展轉化爲患者所需的變革性療法，今天宣佈在《臨床藥理學與治療學：藥物計量學與系統藥理學》的特殊孕期主題期刊上發表了一篇題爲《通過靶向介導的藥物分配建模與模擬來確定妊娠劑量》的手稿。
譯文內容由第三人軟體翻譯。
